Compare AGM & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | ARDX |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | AGM | ARDX |
|---|---|---|
| Price | $174.36 | $7.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $219.00 | $12.95 |
| AVG Volume (30 Days) | 99.8K | ★ 6.3M |
| Earning Date | 02-20-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ 12.85 | N/A |
| EPS | ★ 17.55 | N/A |
| Revenue | $377,946,000.00 | ★ $398,234,000.00 |
| Revenue This Year | $14.80 | $22.65 |
| Revenue Next Year | $9.98 | $31.33 |
| P/E Ratio | $9.94 | ★ N/A |
| Revenue Growth | 8.81 | ★ 58.12 |
| 52 Week Low | $155.00 | $3.21 |
| 52 Week High | $212.24 | $8.17 |
| Indicator | AGM | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 66.23 |
| Support Level | $168.35 | $6.73 |
| Resistance Level | $177.99 | $7.25 |
| Average True Range (ATR) | 4.50 | 0.57 |
| MACD | -0.19 | 0.14 |
| Stochastic Oscillator | 67.72 | 89.03 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.